Less than a tenth of people eligible to benefit from obesity jabs like Wegovy are able to get them, states the World Health Organization as it publishes its initial recommendations on the medications.
Given in excess of 1,000,000,000 people worldwide currently classified as obese, it is calling for broader and more equitable access to these injectable treatments.
Per estimates, over two billion could be living with obesity by 2030 without intervention.
"The latest guidelines recognises that excess weight is a lifelong illness that can be managed with comprehensive and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are key hurdles to widespread availability to the treatments that can help people shift significant body mass, says the agency.
Skinny Jab Shortage
Despite the current most optimistic scenario, the production of these medications could only cover around 100 million people – under 10% of eligible patients, according to the WHO.
The recommendation encourages countries and companies to widen availability, via strategies like patent sharing.
The intellectual property rights on semaglutide – the main component of a leading brand – is scheduled to end in several nations in 2026.
The Way Weight-Loss Jabs Work
These medications mimick a natural hormone to slow digestion, suppress the appetite and enhance satiety so people reduce food intake.
Patients commonly start to lose weight in the initial weeks of beginning the regular doses.
Evidence suggests people may put most of the weight back on within a year of stopping the drug, because their normal hunger come back.
Being overweight or obese elevates your risk for experiencing medical conditions, such as diabetes, heart disease, stroke, and specific cancers.
Excess weight impacts people in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, according to the health agency.
